Martine Zimmermann

CIK: 0001994049

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (12.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)4 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LGND

LIGAND PHARMACEUTICALS INC

Director

CADL

Candel Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

LGND
LIGAND PHARMACEUTICALS INC
Sep 22, 2026
Tax Payment(F)
Direct
115 shares at avg. $298.50$34K
LGND
LIGAND PHARMACEUTICALS INC
Sep 10, 2026
Sale(S)
Direct
1.2K shares at avg. $285.00$342K
CADL
Candel Therapeutics, Inc.
Sep 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
64K shares-
LGND
LIGAND PHARMACEUTICALS INC
Jun 5, 2026
Tax Payment(F)
Direct
182 shares at avg. $237.00$43K
LGND
LIGAND PHARMACEUTICALS INC
Jun 5, 2026
Award(A)
Direct
836 shares-
LGND
LIGAND PHARMACEUTICALS INC
Sep 22, 2025
Tax Payment(F)
Direct
115 shares at avg. $170.77$20K
LGND
LIGAND PHARMACEUTICALS INC
Jun 6, 2025
Tax Payment(F)
Direct
188 shares at avg. $105.99$20K
LGND
LIGAND PHARMACEUTICALS INC
Jun 6, 2025
Award(A)
Direct
1.2K shares-

		Type	Shares	Price		Ownership
Sep 22, 2026	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	115	$298.50	$34,328	Direct
Sep 10, 2026	LGND LIGAND PHARMACEUTICALS INC	Sale(S)	1,200	$285.00	$342,000	Direct
Sep 8, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	64,000	-	-	Direct
Jun 5, 2026	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	182	$237.00	$43,134	Direct
Jun 5, 2026	LGND LIGAND PHARMACEUTICALS INC	Award(A)	836	-	$0	Direct
Sep 22, 2025	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	115	$170.77	$19,639	Direct
Jun 6, 2025	LGND LIGAND PHARMACEUTICALS INC	Tax Payment(F)	188	$105.99	$19,926	Direct
Jun 6, 2025	LGND LIGAND PHARMACEUTICALS INC	Award(A)	1,209	-	-	Direct

1-8 of 8 transactions

About Zimmermann Martine

Zimmermann Martine (SEC CIK 0001994049) files insider reports with the SEC as Director of LIGAND PHARMACEUTICALS INC (LGND) and Director of Candel Therapeutics, Inc. (CADL).

Signal8 holds 7 ownership filings by Zimmermann Martine (1 Form 3, 6 Form 4), filed between Jun 10, 2025 and Sep 24, 2026. Those filings report 8 transactions, from Jun 6, 2025 to Sep 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zimmermann Martine's filings is in NEEDHAM, MA.

Recent filings by Zimmermann Martine

Sep 22, 2026: Tax withholding of LGND shares (Form 4, code F).
Sep 10, 2026: Open-market sale of LGND shares (Form 4, code S).
Sep 8, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 5, 2026: Tax withholding of LGND shares (Form 4, code F).
Jun 5, 2026: Grant or award of LGND shares (Form 4, code A).

Other insiders filing for LIGAND PHARMACEUTICALS INC (LGND)

Reardon Andrew, CLO & Secretary
Espinoza Octavio, Chief Financial Officer
Haas Jason, Director
Davis Todd C, Chief Executive Officer
Sabba Stephen L, Director
Aryeh Jason, Director

How to read Form 4 transaction codes